Planned Parenthood of Southern New England Responds to Supreme Court Granting Stay in Mifepristone Case
Contact: [email protected]
For Immediate Release: April 23, 2023
Mifepristone Will Remain Accessible and on the Market for the Foreseeable Future
New Haven, CT — The Supreme Court’s decision to grant the stay requested by the Department of Justice (DOJ) and Danco in Alliance for Hippocratic Medicine et al v. U.S. Food and Drug Administration et al. means Mifepristone will remain accessible for all residents of Connecticut and Rhode Island for the foreseeable future. The case will now proceed through the Fifth Circuit Court of Appeals and may return on appeal before the Supreme Court.
Statement from Amanda Skinner, President & CEO of Planned Parenthood of Southern New England:
“While we are relieved that science and commonsense prevailed, we should never be in a position where judges are deciding whether people can get safe, effective medicines. This case’s repercussions go far beyond abortion care — it could stifle medical innovation, upend the country’s drug approval process, and put every approved medication in the political crosshairs. Planned Parenthood of Southern New England will never stop fighting to make sure patients have access to the essential health care that they need.”
Mifepristone has been used by over five million people since the FDA approved it more than 20 years ago and has significantly expanded access to reproductive health care, something that is clearly under attack in this country.
Learn more about medication abortion here. For more information about options and a state-by-state guide to get care, go to AbortionFinder.org or call 1-800-230-PLAN.